STAT38m
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
The Financial Express7h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
Prediction: this FTSE 250 trust will beat Rolls-Royce shares over the next 5 years
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...
pharmaphorum17h
AstraZeneca joins KRAS push in cancer with Chinese deal
AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...